Exploring PMMA. To explore a different substance…

Names:
PMMA
4-MMA
METHYL-MA
DOONE
4-MeO-MA
4-Methoxymethamphetamine
N-Methyl-4-methoxyamphetamine
4-Methoxy-N-methylamphetamine
IUPAC name:
1-(4-Methoxyphenyl)-N-methylpropan-2-amine
130 · C11H17NO · 179.259
InChI=1S/C11H17NO/c1-9(12-2)8-10-4-6-11(13-3)7-5-10/h4-7,9,12H,8H2,1-3H3
UGFMBZYKVQSQFX-UHFFFAOYSA-N This stereoisomer Any stereoisomer
CNC(Cc1ccc(cc1)OC)C

Dal Cason, TA. A re-examination of the mono-methoxy positional ring isomers of amphetamine, methamphetamine and phenyl-2-propanone. Forensic Sci. Int., 1 Jan 2001, 119 (3), 168–194. 678 kB. https://doi.org/10.1016/S0379-0738(00)00425-4

Shulgin, AT. TMA, PMA, PMMA, and MDMA effects. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 27 Mar 2003.

Błachut, D; Wojtasiewicz, K; Czarnocki, Z; Szukalski, B. The analytical profile of some 4-methylthioamphetamine (4-MTA) homologues. Forensic Sci. Int., 20 Nov 2009, 192 (1–3), 98–114. 683 kB. https://doi.org/10.1016/j.forsciint.2009.08.009

Steele, TD; Katz, JL; Ricaurte, GA. Evaluation of the neurotoxicity of N-methyl-1-(4-methoxyphenyl)-2-aminopropane (para-methoxymethamphetamine, PMMA). Brain Res., 4 Sep 1992, 589 (2), 349–352. 554 kB. https://doi.org/10.1016/0006-8993(92)91298-S

Staack, RF; Maurer, HH. Metabolism of designer drugs of abuse. Curr. Drug Metab., 1 Jun 2005, 6 (3), 259–274. 104 kB. https://doi.org/10.2174/1389200054021825

Vevelstad, M; Øiestad, EL; Middelkoop, G; Hasvold, I; Lilleng, P; Delaveris, GJM; Eggen, T; Mørland, J; Arnestad, M. The PMMA epidemic in Norway: Comparison of fatal and non-fatal intoxications. Forensic Sci. Int., 10 Jun 2012, 219 (1–3), 151–157. 332 kB. https://doi.org/10.1016/j.forsciint.2011.12.014

EMCDDA. Report on the risk assessment of PMMA, European Monitoring Centre for Drugs and Drug Addiction, Mar 2003. 377 kB. Pages cropped (as was intended but never done, apparently)

Nakanishi, K; Miki, A; Zaitsu, K; Kamata, H; Shima, N; Kamata, T; Katagi, M; Tatsuno, M; Tsuchihashi, H; Suzuki, K. Cross-reactivities of various phenethylamine-type designer drugs to immunoassays for amphetamines, with special attention to the evaluation of the one-step urine drug test Instant-View™, and the Emit® assays for use in drug enforcement. Forensic Sci. Int., 10 Apr 2012, 217 (1–3), 174–181. 397 kB. https://doi.org/10.1016/j.forsciint.2011.11.003

Bustamante, D; Diaz-Véliz, G; Paeile, C; Zapata-Torres, G; Cassels, BK. Analgesic and behavioral effects of amphetamine enantiomers, p-methoxyamphetamine and N-alkyl-p-methoxyamphetamine derivatives. Pharmacol. Biochem. Behav., 1 Oct 2004, 79 (2), 199–212. 404 kB. https://doi.org/10.1016/j.pbb.2004.06.017

Clark, CC. The identification of methoxy-N-methylamphetamines. J. Forensic Sci., 1 Oct 1984, 29 (4), 1056–1071. 423 kB. https://doi.org/10.1520/JFS11772J

Katagi, M; Tsuchihashi, H. Update on clandestine amphetamines and their analogues recently seen in Japan. J. Health Sci., 2002, 48 (1), 14–21. 181 kB. https://doi.org/10.1248/jhs.48.14

Bailey, K; By, AW; Legault, D; Verner, D. Identification of the N-methylated analogs of the hallucinogenic amphetamines and some isomers. J. Assoc. Off. Anal. Chem., 1975, 58 (1), 62–69. 2.0 MB.

Lurie, Y; Gopher, A; Lavon, O; Almog, S; Sulimani, L; Bentur, Y. Severe paramethoxymethamphetamine (PMMA) and paramethoxyamphetamine (PMA) outbreak in Israel. Clin. Toxicol., 1 Jan 2012, 50 (1), 39–43. 93 kB. https://doi.org/10.3109/15563650.2011.635148

Glennon, RA. Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention. Adv. Pharmacol., 2014, 69, 581–620. 564 kB. https://doi.org/10.1016/B978-0-12-420118-7.00015-9

Hyperlab. Hyperlab new compounds. 29 Sep 2014. 232 kB. Note: Contains links to hyperlab.info that require elevated access/karma to follow.

Segawa, H; Iwata, YT; Yamamuro, T; Kuwayama, K; Tsujikawa, K; Kanamori, T; Inoue, H. Differentiation of ring-substituted regioisomers of amphetamine and methamphetamine by supercritical fluid chromatography: Differentiation of ring-substituted regioisomers by supercritical fluid chromatography. Drug Test. Analysis, 1 Mar 2017, 9 (3), 389-398. 1.3 MB. https://doi.org/10.1002/dta.2040

Nichols, DE; Grob, CS. Is LSD toxic? Forensic Sci. Int., 1 Mar 2018, 284 141–145. 415 kB. https://doi.org/10.1016/j.forsciint.2018.01.006

Ogino, M; Naiki, T; Orui, H; Kosone, K; Yamazaki, M. Study of method for identifying phenethylamine drugs. JCCL, 11 Feb 2011, 50, 63-82. 627 kB. Retrieved from http://www.customs.go.jp/ccl_search/e_info_search/drugs/r_50_08_e.pdf

EMCDDA. New drugs in Europe, 2016, European Monitoring Centre for Drugs and Drug Addiction, 1 May 2017. 489 kB.

EMCDDA. New drugs in Europe, 2015, European Monitoring Centre for Drugs and Drug Addiction, 1 May 2016. 1.0 MB.

EMCDDA. New drugs in Europe, 2014, European Monitoring Centre for Drugs and Drug Addiction, 1 Jul 2015. 879 kB.

EMCDDA. New drugs in Europe, 2013, European Monitoring Centre for Drugs and Drug Addiction, 1 Jul 2014. 311 kB.

EMCDDA. New drugs in Europe, 2011, European Monitoring Centre for Drugs and Drug Addiction, 1 Apr 2012. 401 kB.

EMCDDA. New drugs in Europe, 2010, European Monitoring Centre for Drugs and Drug Addiction, 1 May 2011. 700 kB.

King, LA. New phenethylamines in Europe. Drug Test. Analysis, 1 Jul 2014, 6 (7-8), 808-818. 472 kB. https://doi.org/10.1002/dta.1570

Hudson, AL; Lalies, MD; Baker, GB; Wells, K; Aitchison, KJ. Ecstasy, legal highs and designer drug use: A Canadian perspective. Drug Science, Policy and Law, 1 Jan 2014, 1, 2050324513509190. 230 kB. https://doi.org/10.1177/2050324513509190

Nagashima, M; Seto, T; Takahashi, M; Suzuki, J; Yasuda, I. Spectrum data of 4th Governor-designated drugs and the analyses of illegal drugs purchased Apr. 2006 – Mar. 2007. Ann. Rep. Tokyo Metr. Inst. P. H., 1 Jan 2007, 58 89–92. 935 kB. #PMMA LC,MS,NMR,IR,UV

Shulgin, AT. Basic Pharmacology and Effects. In Hallucinogens. A Forensic Drug Handbook; Laing, R; Siegel, JA, Eds., Academic Press, London, 2003; pp 67–137. 6.3 MB.

Nichols, DE. Medicinal chemistry and structure-activity relationships. In Amphetamine and its Analogs; Cho, AK; Segal, DS, Eds., Academic Press, San Diego, CA, 1 Jan 1994; pp 3–41. 6.9 MB.

Simmler, LD; Liechti, ME. Pharmacology of MDMA- and amphetamine-like new psychoactive substances. In Handbook of Experimental Pharmacology; , Springer Berlin Heidelberg, 1 Jan 2018; . 298 kB. https://doi.org/10.1007/164_2018_113

Takahashi, M; Nagashima, M; Suzuki, J; Seto, T; Yasuda, I; Yoshida, T. Creation and application of psychoactive designer drugs data library using liquid chromatography with photodiode array spectrophotometry detector and gas chromatography–mass spectrometry. Talanta, 15 Feb 2009, 77 (4), 1245–1272. 1.2 MB. https://doi.org/10.1016/j.talanta.2008.07.062 #PMMA

Nagashima, M; Seto, T; Takahashi, M; Suzuki, J; Yasuda, I. Spectrum data of the 3rd Governor-designated drugs and the analyses of uncontrolled drugs purchased Apr. 2005 – Mar. 2006. Ann. Rep. Tokyo Metr. Inst. P. H., 1 Jan 2006, 57 109–113. 394 kB. #PMMA

OMMA · 2-Methoxymethamphetamine
Methylephedrine
3,5-Me-4-MPEA
3-MMA · 3-Methoxymethamphetamine
4-EA · 4-Ethoxyamphetamine
MMA
Candicine
2,4-MMA · 5-H-DOM
2406
homo-PMA
N,N-Me-2-MPEA
β,N-Me-2-MPEA
4C-2-MPEA
N-Me-2-EPEA
2-EA
Leptodactyline
N-Et-3-HA
N,N-Me-3-MPEA
N-Et-3-MPEA
4C-3-MPEA
N-Me-3-EPEA
3-EA
PHMMA
PHEA
N,N-Me-4-MPEA
β,N-Me-4-MPEA
α,α-Me-PMPEA
α-Et-MPEA
N-Me-4-EPEA
4-PPEA
2,3-HMeMMPEA
2,3-HMeMA
2,3-MMeA
β-HO-3,4,N-MePEA
3,5-Me-PHA
2,6-Me-MPEA
4,6-Me-2-MPEA
N-(2-Hydroxyethyl)amphetamine
10110
DMA N-oxide
N-MeO-PMeA
10527
10159
10145
HM-α-EPEA
10091
4-Methoxy-2-methylamphetamine
Mexiletine
4-Methylephedrine
18 October 2018 · Creative Commons BY-NC-SA ·